Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-treatment drug resistance surveillance among ART- Naive HIV-1 patients in Tunisia.

Virusdisease·2026
Same author

Prevalence of celiac disease in a Tunisian cohort.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

[Biologic National Registry (BINAR) protocol: Design and Rationale of the Tunisian clinical multicentric study of efficacy and safety of biologics in Rheumatoid arthritis and Spondyloarthritis].

La Tunisie medicale·2026
Same author

Study of Interleukin 1β Gene Polymorphisms in Tunisian Paediatric Population With Cystic Echinococcosis.

Parasite immunology·2026
Same author

TLR4 rs4986790 and TLR9 rs5743836 Polymorphisms and Their Association With Clinical Outcomes of Leishmania infantum Infection in Tunisia.

Cureus·2026
Same author

Do the Psoriatic Arthritis Impact of Disease's cutoffs vary across ethnicities? Insights from the TACTIC initiative.

Clinical rheumatology·2026

Related Experiment Video

Updated: Jun 5, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Systemic lupus erythematosus in the elderly.

Achouak Achour1, Amani Mankaï, Yosra Thabet

  • 1Research unit (03/UR/07-02), Faculty of pharmacy, Rue Avicenne, 5000 Monastir, Tunisia.

Rheumatology International
|January 25, 2011
PubMed
Summary

Systemic Lupus Erythematosus (SLE) in patients over 65 presents unique symptoms. Early recognition of these distinct clinical and laboratory features is crucial for accurate diagnosis and management in elderly SLE patients.

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Related Experiment Videos

Last Updated: Jun 5, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Geriatrics

Background:

  • Late-onset Systemic Lupus Erythematosus (SLE) is uncommon, with onset typically occurring before age 65.
  • Understanding the specific clinical and laboratory characteristics of SLE in the elderly is essential for timely diagnosis and effective management.

Purpose of the Study:

  • To retrospectively investigate the clinical and laboratory features of SLE patients aged 65 years and older.
  • To identify distinct patterns in elderly-onset SLE compared to the classic form of the disease.

Main Methods:

  • Retrospective analysis of 18 elderly patients (≥65 years) diagnosed with SLE between 1994 and 2009.
  • Patients met at least 4 of the 11 revised American College of Rheumatology (ACR) criteria for SLE.
  • Data collected included clinical signs, laboratory findings, and immunological markers.

Main Results:

  • The frequency of SLE in the elderly population studied was 5.3%.
  • The median age of the elderly SLE patients was 70 years, with a female-to-male ratio of 5:1.
  • Common clinical manifestations included anemia (83.3%), arthralgia (55.5%), arthritis (38.9%), and malar rash (33.3%). Proteinuria and neuropsychiatric symptoms were observed in 27.8% of cases, and pericarditis in 16.7%.
  • Key autoantibodies detected were anti-double-stranded DNA (anti-dsDNA) (66.7%), anti-nucleosome (50%), anti-SSA/anti-RNP (27.8%), anti-Sm (22%), and anti-SSB (11%).

Conclusions:

  • Elderly patients with SLE exhibit distinct clinical and biological manifestations compared to younger individuals.
  • Increased clinical vigilance and awareness are necessary to avoid diagnostic delays or misdiagnosis in this specific subgroup of SLE patients.